Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (391-400 of 456) with videos related to

Pageof 46
Sort By:
Annals of Surgery|June 16, 2025
Global Variations in Patterns of Care for Retroperitoneal SarcomaHayden Snow, Marco Fiore, Jing Xie, et al.
The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.
The Lancet. Oncology|September 17, 2020
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trialSylvie Bonvalot, Alessandro Gronchi, Cécile Le Péchoux, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.
The Journal of Experimental Medicine|April 13, 2019
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <sup></sup> mutationSusana García-Silva, Alberto Benito-Martín, Sara Sánchez-Redondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyMario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.
Annals of Surgery|December 22, 2025
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar)Alessandra Borghi, Marco Fiore, Gabriele Tiné, et al.
Eclinicalmedicine|March 5, 2026
Neoadjuvant radiotherapy for primary retroperitoneal well-differentiated liposarcoma: a Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) propensity score matched analysisMark Fairweather, Megan Sulciner, Joshua S Jolissaint, et al.
Pageof 46

Showing results (391-400 of 456) with videos related to

Sort By:
Pageof 46
Annals of Surgery|June 16, 2025
Global Variations in Patterns of Care for Retroperitoneal SarcomaHayden Snow, Marco Fiore, Jing Xie, et al.
The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.
The Lancet. Oncology|September 17, 2020
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trialSylvie Bonvalot, Alessandro Gronchi, Cécile Le Péchoux, et al.
The Lancet. Oncology|October 20, 2022
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trialGeorgina V Long, Jason J Luke, Muhammad A Khattak, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2024
Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanomaEleanor E Handel, Janet McKeown, Joe Wei, et al.
The Journal of Experimental Medicine|April 13, 2019
Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <sup></sup> mutationSusana García-Silva, Alberto Benito-Martín, Sara Sánchez-Redondo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2022
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II TrialPaolo A Ascierto, Mario Mandalà, Pier Francesso Ferrucci, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2024
Combined immunotherapy in melanoma patients with brain metastases: A multicenter international studyMario Mandalà, Paul Lorigan, Maria Chiara Sergi, et al.
Annals of Surgery|December 22, 2025
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar)Alessandra Borghi, Marco Fiore, Gabriele Tiné, et al.
Eclinicalmedicine|March 5, 2026
Neoadjuvant radiotherapy for primary retroperitoneal well-differentiated liposarcoma: a Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) propensity score matched analysisMark Fairweather, Megan Sulciner, Joshua S Jolissaint, et al.
Pageof 46